Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.95. Cortexyme shares last traded at $1.91, with a volume of 382,771 shares changing hands.
Cortexyme Trading Up 6.1%
The firm has a 50-day moving average of $1.72 and a 200 day moving average of $1.54. The stock has a market capitalization of $57.59 million, a price-to-earnings ratio of -0.64 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Read More
- Five stocks we like better than Cortexyme
- NYSE Stocks Give Investors a Variety of Quality Options
- onsemi Places a $6 Billion Bet on Its Own Stock
- Do ETFs Pay Dividends? What You Need to Know
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- What Are Dividend Contenders? Investing in Dividend Contenders
- End the Year Strong With These 3 Comeback Champions
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
